Entera Bio Ltd. (ENTX)
| Market Cap | 515.96M +527.7% |
| Revenue (ttm) | n/a -76.8% |
| Net Income | -17.03M |
| EPS | -0.35 |
| Shares Out | 173.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 613,718 |
| Open | 3.020 |
| Previous Close | 2.960 |
| Day's Range | 2.945 - 3.030 |
| 52-Week Range | 0.910 - 4.200 |
| Beta | 1.39 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+202.01%) |
| Earnings Date | Aug 7, 2026 |
About ENTX
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist pept... [Read more]
Financial Performance
In 2025, Entera Bio's revenue was $42,000, a decrease of -76.80% compared to the previous year's $181,000. Losses were -$11.44 million, 19.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ENTX stock is "Strong Buy." The 12-month stock price target is $9.0, which is an increase of 202.01% from the latest price.
News
Entera Bio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Entera Bio (ENTX) with an Overweight rating. Entera is positioned for significant upside with EB613, a potentially first-in-class oral osteoanabolic for osteopo...
Entera Bio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Entera Bio (ENTX) with an Overweight rating.
Leerink bullish on Entera Bio, initiates with an Outperform
As previously reported, Leerink initiated coverage of Entera Bio (ENTX) with an Outperform rating and $9 price target representing about 200% upside to the current price of $3.03. The firm…
Entera Bio initiated with an Outperform at Leerink
Leerink initiated coverage of Entera Bio (ENTX) with an Outperform rating and $9 price target
Correction: Entera to Participate in Upcoming Fall Investor Conferences
TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief E...
Entera to Participate in Upcoming Fall Investor Conferences
TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief E...
Entera Bio files to sell 134.8M ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 134.8M ordinary shares. The company is not selling any shares under…
Entera Bio Registration statement: Registration filing
Entera Bio filed a registration statement on August 21, 2026, providing details about a securities offering with the SEC.
Entera Bio names Riccardo Paolo Camisasca as chief medical officer
Entera Bio (ENTX) announced the appointment of Riccardo Paolo Camisasca as chief medical officer. Most recently, he served as global head of research and development at Sumitomo Pharma Switzerland. Pu...
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Dr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis Appointment further strengthens ...
Entera Bio Transcript: Canaccord Genuity's 46th Annual Growth Conference
EB613, an oral anabolic peptide for osteoporosis, is advancing to a streamlined phase III trial after FDA alignment, targeting a major treatment gap between antiresorptives and injectables. The candidate aims to improve bone health for a broader patient population and offers strong pharmacoeconomic potential.
Entera Announces Second Quarter 2026 Financial Results and Business Updates
U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteop...
Entera Bio Quarterly report: Q2 2026
Entera Bio has published its Q2 2026 quarterly earnings report on August 7, 2026.
Entera Bio Earnings release: Q2 2026
Entera Bio released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase ...
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
TEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief Executive...
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
MIAMI, July 29, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Entera Bio Ltd.
Entera Bio announces $275M private placement
Entera Bio (ENTX) announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing. The Private Placement is expected to result in aggregate gross p...
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
The offering is led by existing investor BVF Partners L.P. Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB...
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market
Entera Bio (NASDAQ: ENTX) may have just cleared its biggest regulatory hurdle yet. The FDA has provided positive feedback on the Phase 3 protocol for EB613, the company's oral osteoporosis tablet, cre...
Entera Bio gets FDA feedback on registrational protocol for EB613
Entera Bio (ENTX) announced that it has received feedback from the FDA on its Phase 3 registrational protocol for EB613, the first oral anabolic tablet in development for the treatment…
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera's plan to submi...
Entera Bio and Opko Health present preclinical data for oral peptides
Entera Bio (ENTX) and Opko Health (OPK) reported preclinical data at the ENDO 2026 annual meeting for their co-developed EB612 and EB618 oral peptide programs. For EB612, a long-acting oral…
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected ...
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera's Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026